Controlling cardiomyocyte length: the role of renin and PPAR-{gamma}

Cardiovasc Res. 2011 Feb 1;89(2):344-52. doi: 10.1093/cvr/cvq313. Epub 2010 Sep 30.

Abstract

Aims: Renin and peroxisome proliferator-activated receptor (PPAR-γ) interact directly with cardiomyocytes and influence protein synthesis. We investigated their effects and interaction on the size of cardiomyocytes.

Methods and results: Effects of renin and PPAR-γ activation were studied in cultured adult rat ventricular cardiomyocytes, transgenic mice with a cardiomyocyte-restricted knockout of PPAR-γ, and transgenic rats overexpressing renin, TGR(mRen2)27. The length and width of cardiomyocytes were analysed 24 h after administration of factors. Renin caused an unexpected effect on the length of cardiomyocytes that was inhibited by mannose-6-phosphate and monensin, but not by administration of glucose-6-phosphate. Endothelin-1 used as a classical pro-hypertrophic agonist increased cell width but not cell length. Renin caused an activation of p38 and p42/44 mitogen-activated protein (MAP) kinases. The latter activation was impaired by mannose-6-phosphate. Inhibition of p42/44 but not of p38 MAP kinase activation attenuated the effect of renin on cell length. In contrast, activation of PPAR-γ reduced cell length. Feeding wild-type mice with pioglitazone, a PPAR-γ agonist, reduced cell length. Cardiomyocytes isolated from PPAR-γ knockout mice were longer, and their length was not affected by pioglitazone. Cardiomyocytes isolated from TGR(mRen2)27 rats were longer than those of non-transgenic littermates. Cell length was reduced by feeding these mice with pioglitazone. Pioglitazone affected cell length independent of blood pressure.

Conclusion: The length of cardiomyocytes is controlled by the activation of cardiac-specific mannose-6-phosphate/insulin-like growth factor II receptors and activation of PPAR-γ. This type of cell size modification differs from that of any other known pro-hypertrophic agonists.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Captopril / pharmacology
  • Cell Shape* / drug effects
  • Cells, Cultured
  • Endothelin-1 / metabolism
  • Enzyme Activation
  • Flavonoids / pharmacology
  • Imidazoles / pharmacology
  • Mannosephosphates / metabolism
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred DBA
  • Mice, Knockout
  • Mitogen-Activated Protein Kinases / metabolism
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • PPAR gamma / agonists
  • PPAR gamma / deficiency
  • PPAR gamma / genetics
  • PPAR gamma / metabolism*
  • Pioglitazone
  • Protein Kinase Inhibitors / pharmacology
  • Pyridines / pharmacology
  • Rats
  • Rats, Transgenic
  • Receptor, IGF Type 2 / metabolism
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Recombinant Proteins / metabolism
  • Renin / genetics
  • Renin / metabolism*
  • Thiazolidinediones / pharmacology
  • Time Factors

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Endothelin-1
  • Flavonoids
  • Imidazoles
  • Mannosephosphates
  • PPAR gamma
  • Protein Kinase Inhibitors
  • Pyridines
  • Receptor, IGF Type 2
  • Receptors, Cytoplasmic and Nuclear
  • Recombinant Proteins
  • Ren2 protein, mouse
  • Thiazolidinediones
  • cation-dependent mannose-6-phosphate receptor
  • mannose-6-phosphate
  • Captopril
  • Mitogen-Activated Protein Kinases
  • Renin
  • 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Pioglitazone